RATIONALE: Idiopathic pulmonary fibrosis is a progressive disease with high mortality. Although most patients have a slow, progressive course, some patients will have an acute deterioration in function or acute exacerbation, which carries a poor prognosis. In some cases, acute deterioration is associated with infection. Herpesviruses have been associated with this disease. Fibrocytes have also been shown to be important in the pathogenesis of pulmonary fibrosis. OBJECTIVES: To develop a murine model for infectious exacerbation of preexisting fibrosis, and provide mechanistic insight into the role of herpesviruses in fibrotic disease. METHODS: We used a model of fluorescein isothiocyanate-induced pulmonary fibrosis in mice. Infection with a murine gammaherpesvirus was given at time of established lung fibrosis. Measurements were made at the time of peak lytic viral replication. MEASUREMENTS AND MAIN RESULTS: We demonstrate that infection with gammaherpesvirus can exacerbate established fluorescein isothiocyanate-induced fibrosis evidenced by increased total lung collagen, histologic changes of acute lung injury, and diminished lung function. Gammaherpesvirus can exacerbate preexisting fibrosis in a Th1 cytokine environment and in the absence of Th2 cytokines. Gammaherpesvirus increases fibrocyte recruitment to the lung in wild-type, but not CCR2(-/-) mice, in part because viral infection up-regulates production of CCL2 and CCL12, chemokines important for fibrocyte recruitment. In contrast, mouse adenovirus infection did not exacerbate collagen deposition. CONCLUSIONS: These data provide a new model for gammaherpesvirus exacerbation of established pulmonary fibrosis. The up-regulation of chemokines during viral infection and subsequent recruitment of fibrocytes to the lung likely contribute to augmentation of pulmonary fibrosis.
RATIONALE: Idiopathic pulmonary fibrosis is a progressive disease with high mortality. Although most patients have a slow, progressive course, some patients will have an acute deterioration in function or acute exacerbation, which carries a poor prognosis. In some cases, acute deterioration is associated with infection. Herpesviruses have been associated with this disease. Fibrocytes have also been shown to be important in the pathogenesis of pulmonary fibrosis. OBJECTIVES: To develop a murine model for infectious exacerbation of preexisting fibrosis, and provide mechanistic insight into the role of herpesviruses in fibrotic disease. METHODS: We used a model of fluorescein isothiocyanate-induced pulmonary fibrosis in mice. Infection with a murine gammaherpesvirus was given at time of established lung fibrosis. Measurements were made at the time of peak lytic viral replication. MEASUREMENTS AND MAIN RESULTS: We demonstrate that infection with gammaherpesvirus can exacerbate established fluorescein isothiocyanate-induced fibrosis evidenced by increased total lung collagen, histologic changes of acute lung injury, and diminished lung function. Gammaherpesvirus can exacerbate preexisting fibrosis in a Th1 cytokine environment and in the absence of Th2 cytokines. Gammaherpesvirus increases fibrocyte recruitment to the lung in wild-type, but not CCR2(-/-) mice, in part because viral infection up-regulates production of CCL2 and CCL12, chemokines important for fibrocyte recruitment. In contrast, mouse adenovirus infection did not exacerbate collagen deposition. CONCLUSIONS: These data provide a new model for gammaherpesvirus exacerbation of established pulmonary fibrosis. The up-regulation of chemokines during viral infection and subsequent recruitment of fibrocytes to the lung likely contribute to augmentation of pulmonary fibrosis.
Authors: T Maeyama; K Kuwano; M Kawasaki; R Kunitake; N Hagimoto; N Hara Journal: Am J Physiol Lung Cell Mol Physiol Date: 2001-06 Impact factor: 5.464
Authors: G B Huffnagle; R M Strieter; T J Standiford; R A McDonald; M D Burdick; S L Kunkel; G B Toews Journal: J Immunol Date: 1995-11-15 Impact factor: 5.422
Authors: Ana L Mora; Edilson Torres-González; Mauricio Rojas; Jianguo Xu; Jeffrey Ritzenthaler; Samuel H Speck; Jesse Roman; Kenneth Brigham; Arlene Stecenko Journal: Am J Respir Crit Care Med Date: 2007-03-15 Impact factor: 21.405
Authors: Payal N Naik; Jeffrey C Horowitz; Thomas A Moore; Carol A Wilke; Galen B Toews; Bethany B Moore Journal: J Gerontol A Biol Sci Med Sci Date: 2011-12-21 Impact factor: 6.053
Authors: Joshua S Stoolman; Kevin M Vannella; Stephanie M Coomes; Carol A Wilke; Thomas H Sisson; Galen B Toews; Bethany B Moore Journal: Am J Physiol Lung Cell Mol Physiol Date: 2010-10-29 Impact factor: 5.464
Authors: Kazuhisa Konishi; Kevin F Gibson; Kathleen O Lindell; Thomas J Richards; Yingze Zhang; Rajiv Dhir; Michelle Bisceglia; Sebastien Gilbert; Samuel A Yousem; Jin Woo Song; Dong Soon Kim; Naftali Kaminski Journal: Am J Respir Crit Care Med Date: 2009-04-10 Impact factor: 21.405
Authors: MeiLan K Han; Yueren Zhou; Susan Murray; Nabihah Tayob; Imre Noth; Vibha N Lama; Bethany B Moore; Eric S White; Kevin R Flaherty; Gary B Huffnagle; Fernando J Martinez Journal: Lancet Respir Med Date: 2014-04-21 Impact factor: 30.700
Authors: Bethany B Moore; William E Lawson; Tim D Oury; Thomas H Sisson; Krishnan Raghavendran; Cory M Hogaboam Journal: Am J Respir Cell Mol Biol Date: 2013-08 Impact factor: 6.914
Authors: Elizabeth A Turpin; Aurita Antao-Menezes; Mark F Cesta; James B Mangum; Duncan G Wallace; Edilberto Bermudez; James C Bonner Journal: Respir Res Date: 2010-02-22